Lim Hui Yin, Ho Prahlad
Department of Haematology, Northern Health, 185 Cooper Street, Epping VIC 3076, Australia.
Department of Haematology, Austin Health, Studley Road, Heidelberg VIC 3084, Australia.
Dent J (Basel). 2016 Mar 19;4(1):7. doi: 10.3390/dj4010007.
Direct oral anticoagulants (DOACs) have led to a paradigm shift in the field of anticoagulation, providing safe and convenient anticoagulation without the need for regular blood testing. Currently, there are three major DOACs available-Factor Xa inhibitors (apixaban and rivaroxaban) and direct thrombin inhibitors (dabigatran)-that are available for use in atrial fibrillation and venous thromboembolism. While these agents have been shown to be as effective as warfarin, with a similar or better bleeding profile, there remains some concern of the use of these drugs in vulnerable populations, such as the frail elderly patients; particularly since reversal agents and drug monitoring are not routinely available. We aim to provide a review of the use of DOACs and the impact of DOACs on dental treatment in the elderly population.
直接口服抗凝剂（DOACs）已在抗凝领域引发了一场范式转变，提供了安全便捷的抗凝治疗，无需定期进行血液检测。目前，有三种主要的DOACs可供使用——Xa因子抑制剂（阿哌沙班和利伐沙班）和直接凝血酶抑制剂（达比加群），可用于治疗心房颤动和静脉血栓栓塞。虽然这些药物已被证明与华法林一样有效，且出血情况相似或更好，但在脆弱人群，如体弱的老年患者中使用这些药物仍存在一些担忧；特别是因为逆转剂和药物监测并非常规可用。我们旨在综述DOACs的使用情况以及DOACs对老年人群牙科治疗的影响。
